Which medication, aripiprazole (Abilify) or risperidone (Risperdal), is associated with a lower incidence of catatonia?

Aripiprazole (Abilify) Causes Less Catatonia Than Risperidone (Risperdal)

Based on the available evidence, aripiprazole (Abilify) is associated with a significantly lower risk of catatonia compared to risperidone (Risperdal), and may actually be therapeutic for catatonia rather than causative.

Key Evidence Supporting This Recommendation

Risperidone's Association with Catatonia

The FDA label for Risperdal does not specifically list catatonia as a warning or adverse reaction 1. However, multiple case reports document risperidone-induced catatonia:

• A 61-year-old patient with schizophrenia developed severe, dose-dependent catatonia on risperidone 5 mg daily, which resolved immediately upon switching to clozapine 2
• A 23-year-old woman developed catatonia-like immobility, somnolence, and refusal of food on risperidone 3 mg twice daily, with rapid complete recovery within 24 hours after discontinuation and switch to olanzapine 3
• Paliperidone (the active metabolite of risperidone) has also been associated with catatonia onset 4
• A 16-year-old with early-onset schizophrenia developed acute catatonic symptoms during risperidone reintroduction 5

Aripiprazole's Therapeutic Role in Catatonia

In stark contrast, aripiprazole appears to treat rather than cause catatonia:

• A patient with severe catatonic depression experienced rapid resolution of catatonic symptoms after just 3 days of aripiprazole 25 mg 6
• Multiple case reports demonstrate aripiprazole's effectiveness in treating catatonia in schizophrenia, major depression, and brief psychotic disorder 7
• A 16-year-old with catatonic schizophrenia achieved symptom resolution only after adding low-dose aripiprazole to lorazepam 5
• A 2025 systematic review of 175 antipsychotic trials found that aripiprazole had equivocal outcomes (neither predominantly beneficial nor harmful), while risperidone tended to be reported as beneficial in some cases but was also associated with catatonia induction 8

Mechanism Explaining the Difference

Aripiprazole's unique pharmacology likely explains its safety advantage:

• Partial D2 agonist/antagonist: Acts as both antagonist and partial agonist depending on cellular environment, providing a more balanced dopaminergic effect 6
• GABA enhancement: Enhances GABA transmission in certain brain areas; low GABA activity contributes to catatonia 6
• 5-HT2C partial agonism: May contribute to antidepressant properties relevant in catatonic depression 6
• Lower risk profile: Carries much lower risk of complications compared to other antipsychotics 6

Risperidone, as a more potent D2 antagonist without partial agonist properties, appears more likely to precipitate catatonia through excessive dopamine blockade.

Clinical Pitfalls to Avoid

1. Don't assume all atypical antipsychotics are equivalent for catatonia risk—the pharmacological profiles matter significantly
2. Recognize medication-induced catatonia early: Look for escalating somnolence, immobility, mutism, and refusal of food/fluids in patients on risperidone
3. Don't delay switching medications: When risperidone-induced catatonia is suspected, rapid discontinuation and substitution can lead to recovery within 24 hours 3
4. Consider aripiprazole as treatment: High-dose aripiprazole (≥25 mg/day) should be considered as an alternative to ECT and benzodiazepines when treating catatonia 6

Bottom Line

Choose aripiprazole over risperidone when catatonia risk is a concern. If a patient on risperidone develops catatonic symptoms, discontinue immediately and consider switching to aripiprazole or olanzapine rather than continuing risperidone.